Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
19.17B | 17.50B | 15.96B | 14.05B | 13.33B | Gross Profit |
11.54B | 10.94B | 9.68B | 8.44B | 7.95B | EBIT |
1.25B | 1.29B | 1.14B | 1.17B | 1.36B | EBITDA |
2.86B | 2.59B | 2.31B | 1.73B | 2.10B | Net Income Common Stockholders |
854.56M | 739.69M | 846.76M | 483.62M | 1.17B |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
8.46B | 6.66B | 6.68B | 4.59B | 4.67B | Total Assets |
18.03B | 15.69B | 14.57B | 11.51B | 11.06B | Total Debt |
3.02B | 2.01B | 1.96B | 693.48M | 524.70M | Net Debt |
-5.44B | -4.65B | -4.72B | -3.90B | -4.15B | Total Liabilities |
8.54B | 7.03B | 6.62B | 4.36B | 3.77B | Stockholders Equity |
9.46B | 8.64B | 7.93B | 7.13B | 7.00B |
Cash Flow | Free Cash Flow | |||
1.23B | 267.18M | 293.69M | 327.16M | 614.76M | Operating Cash Flow |
2.81B | 2.20B | 1.68B | 1.56B | 1.90B | Investing Cash Flow |
-1.60B | -1.80B | -1.14B | -1.19B | -1.16B | Financing Cash Flow |
280.79M | -645.92M | 763.68M | -822.04M | -64.61M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
81 Outperform | ¥27.31B | 13.36 | 4.14% | 13.49% | 24.76% | ||
80 Outperform | ¥21.28B | 21.98 | 0.88% | 15.09% | 83.99% | ||
69 Neutral | ¥23.15B | 32.02 | 1.85% | 7.60% | -6.99% | ||
66 Neutral | ¥23.25B | 20.55 | 1.54% | -2.15% | -13.31% | ||
65 Neutral | ¥23.85B | 42.97 | ― | -17.30% | ― | ||
62 Neutral | $11.81B | 10.34 | -7.44% | 2.91% | 7.41% | -7.93% |
GMO GlobalSign Holdings K.K. reported its consolidated financial results for the first quarter of 2025, showing a slight increase in net sales by 4% year-on-year to ¥4,909 million. However, the company experienced a decline in operating profit, ordinary profit, and profit attributable to owners of the parent, with decreases of 32.6%, 39.1%, and 39.6% respectively. The company’s financial position showed a slight decrease in total assets and net assets compared to the end of 2024, with a capital adequacy ratio of 50.3%. Despite these challenges, the company forecasts a positive outlook for the full fiscal year ending December 31, 2025, with expected growth in net sales and profits.